NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
Clinical Trials
32 trialsNCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT04094610 2025-11-19
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT01837862 2024-07-05
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Northwell Health
Phase 1/2 Completed
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT03245151 2023-08-30
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Eisai Inc.
Phase 1/2 Completed
NCT02661282 2023-06-18
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04730349 2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2 Terminated
NCT02330562 2022-06-08
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Celgene
Phase 1/2 Completed
NCT01110876 2021-08-25
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01051557 2021-07-19
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02273739 2021-02-23
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
Phase 1/2 Completed
NCT00275067 2020-02-25
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
Northwestern University
Phase 1/2 Unknown
NCT02496741 2020-01-09
MACIST
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT01454596 2019-08-21
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01977677 2018-10-23
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Stanford University
Phase 1/2 Completed
NCT00004868 2018-06-27
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00010049 2018-06-27
Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00022724 2018-06-26
CCI-779 in Treating Patients With Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT01648348 2018-05-23
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01740570 2018-01-19
Phase I/II Cabazitaxel for Recurrent Malignant Glioma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT01026493 2017-07-02
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT01125800 2017-03-20
A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
Novartis
Phase 1/2 Completed
NCT00124657 2015-12-04
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
St. Jude Children's Research Hospital
Phase 1/2 Completed
NCT00112736 2015-06-15
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00003461 2014-08-21
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors
Duke University
Phase 1/2 Completed
NCT00002752 2014-07-16
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers
Duke University
Phase 1/2 Completed
NCT00006268 2013-06-24
Immunotoxin Therapy in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00003478 2013-02-20
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors
Duke University
Phase 1/2 Completed
NCT00352313 2012-05-02
ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed